Trimethoprim, Sulfamethoxazole Drug Combination
"Trimethoprim, Sulfamethoxazole Drug Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.
Descriptor ID |
D015662
|
MeSH Number(s) |
D02.065.884.725.867.500 D02.092.146.807.867.500 D02.886.590.700.725.867.500 D03.383.742.906.500 D26.310.875
|
Concept/Terms |
Trimethoprim, Sulfamethoxazole Drug Combination- Trimethoprim, Sulfamethoxazole Drug Combination
- Centrin
- Cotrimoxazole
- Eslectin
- Insozalin
- TMP-SMX
- Trimethoprim-Sulfamethoxazole
- Trimethoprim Sulfamethoxazole
- Sulfamethoxazole-Trimethoprim Combination
- Sulfamethoxazole Trimethoprim Combination
- Trimethoprim-Sulfamethoxazole Combination
- Trimethoprim Sulfamethoxazole Combination
- Trimezole
- Co-Trimoxazole
- Co Trimoxazole
- TMP SMX
- Centran
- Trimedin
|
Below are MeSH descriptors whose meaning is more general than "Trimethoprim, Sulfamethoxazole Drug Combination".
Below are MeSH descriptors whose meaning is more specific than "Trimethoprim, Sulfamethoxazole Drug Combination".
This graph shows the total number of publications written about "Trimethoprim, Sulfamethoxazole Drug Combination" by people in this website by year, and whether "Trimethoprim, Sulfamethoxazole Drug Combination" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 0 | 2 | 2 |
1996 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2002 | 0 | 2 | 2 |
2004 | 1 | 0 | 1 |
2005 | 1 | 0 | 1 |
2006 | 0 | 2 | 2 |
2007 | 0 | 1 | 1 |
2008 | 1 | 2 | 3 |
2009 | 1 | 0 | 1 |
2010 | 0 | 3 | 3 |
2011 | 0 | 3 | 3 |
2012 | 2 | 2 | 4 |
2013 | 0 | 2 | 2 |
2014 | 1 | 3 | 4 |
2015 | 1 | 1 | 2 |
2017 | 0 | 2 | 2 |
2018 | 1 | 0 | 1 |
2020 | 1 | 2 | 3 |
2021 | 2 | 1 | 3 |
2022 | 0 | 1 | 1 |
2023 | 0 | 1 | 1 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Trimethoprim, Sulfamethoxazole Drug Combination" by people in Profiles.
-
Determining a urinary-specific antibiogram and risk factors of trimethoprim/sulfamethoxazole, ciprofloxacin and multidrug resistance among Enterobacterales in primary care. J Antimicrob Chemother. 2024 03 01; 79(3):559-563.
-
Predicting Antibiotic Susceptibility Among Patients With Recurrent Urinary Tract Infection Using a Prior Culture. J Urol. 2024 01; 211(1):144-152.
-
Outpatient antibiogram and predictors of ciprofloxacin and trimethoprim-sulfamethoxazole resistant urinary tract infections. Ann Fam Med. 2022 04 01; (20 Suppl 1).
-
Case Report: Molecular Diagnosis of Cystoisospora belli in a Severely Immunocompromised Patient with HIV and Kaposi Sarcoma. Am J Trop Med Hyg. 2021 11 29; 106(2):678-680.
-
Relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children: A French multicenter study. PLoS One. 2021; 16(9):e0257217.
-
Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial. JAMA. 2021 07 27; 326(4):324-331.
-
Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial. JAMA. 2021 05 11; 325(18):1841-1851.
-
Mediastinal Lymphadenitis Due to Nocardia Infection. J Bronchology Interv Pulmonol. 2020 Jul; 27(3):e48-e51.
-
Retrospective Analysis of Antimicrobial Susceptibility Profiles of Nocardia Species from a Tertiary Hospital and Reference Laboratory, 2011 to 2017. Antimicrob Agents Chemother. 2020 02 21; 64(3).
-
Full-Body Rash and Fever in a 15-Year-Old Male. Clin Pediatr (Phila). 2020 09; 59(9-10):933-937.